New Products
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 20511 | PDD4091 | 1373651-41-2 | ≧98.0% |  |
| PDD4091 是一种新颖的G6PD抑制剂。 | ||||
| 20512 | BDTX-1535 | 2607829-38-7 | ≧98.0% |  |
| BDTX-1535 是一种突变选择性、不可逆的第四代 EGFR 抑制剂。 | ||||
| 20514 | NMS-293 ( NMS-P293 ) | 1606996-12-6 | ≧98.0% | _1606996-12-6.png) |
| NMS-293 是 Nerviano Medical Sciences 处于早期临床开发阶段的 PARP-1 抑制 | ||||
| 20576 | STX-721 | 2765525-82-2 | ≧98.0% |  |
| STX-721 is a next-generation, orally delivered therapy, designed with potential best- | ||||
| 20639 | SOP1812 (QN-302) | 2546091-70-5 | ≧98.0% | _2546091-70-5.png) |
| QN-302 是一种 G4选择性转录抑制剂。 | ||||
| 20640 | AAG-1 ( FLAG-003 ) | 1614235-14-1 | ≧98.0% |  |
| FLAG-003 是一种多效水溶性小分子治疗药物，旨在通过两种成熟的作 | ||||
| 20641 | KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) | 2082765-42-0 | ≧98.0% | _2082765-42-0.png) |
| KP-302 ( Synonyms: Lucid-21-302 ; Lucid-MS ) 是一种蛋白质精氨酸脱亚胺酶的 | ||||
| 20642 | OATD-02 | 2146132-73-0 | ≧98.0% |  |
| OATD-02 是一种口服双精氨酸酶抑制剂（ARG1 和 ARG2），目前在 Molecu | ||||
| 20650 | Sonrotoclax (BGB-11417) | 2383086-06-2 | ≧98.0% |  |
| Sonrotoclax is an antineoplastic. | ||||
| 262401 | MRTX1719 | 2630904-45-7 | ≧96.0% | |
| MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively | ||||
| 24004 | T-1095 | 209746-59-8 | ≧96.0% |  |
| T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). | ||||
| 24008 | RNK-05047 | 2503036-46-0 | ≧98.0% |  |
| RNK-05047 为BRD4降解剂，其在小鼠荷瘤异种移植模型中展现出显著抑 | ||||